Nanobiotix (NASDAQ:NBTX) Price Target Raised to $36.00 at Guggenheim

Nanobiotix (NASDAQ:NBTX) had its price target boosted by Guggenheim from $26.00 to $36.00 in a report published on Thursday,Benzinga reports. They currently have a buy rating on the stock.

NBTX has been the subject of a number of other reports. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Nanobiotix currently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Nanobiotix Trading Down 8.9%

NBTX opened at $31.04 on Thursday. The stock has a fifty day simple moving average of $28.10 and a two-hundred day simple moving average of $23.25. Nanobiotix has a 12-month low of $2.99 and a 12-month high of $41.89.

Nanobiotix (NASDAQ:NBTX) last announced its earnings results on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $3.42 million for the quarter. Research analysts forecast that Nanobiotix will post -1.18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nanobiotix

Several large investors have recently modified their holdings of the stock. Millennium Management LLC bought a new position in Nanobiotix in the 4th quarter worth about $390,000. Marshall Wace LLP bought a new stake in Nanobiotix during the 4th quarter valued at about $220,000. Optiver Holding B.V. purchased a new position in Nanobiotix in the third quarter worth about $101,000. Finally, Royal Bank of Canada lifted its stake in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Trending Headlines about Nanobiotix

Here are the key news stories impacting Nanobiotix this week:

• Positive Sentiment: Guggenheim raised its price target on NBTX from $26 to $36 and initiated/maintained a “Buy” rating — a supportive analyst upgrade that signals ~16% upside from the cited price and may attract fresh buying interest. Benzinga Coverage
• Positive Sentiment: HC Wainwright issued a bullish long-term EPS view, forecasting FY2030 EPS of $2.33 (well above consensus for current-year losses), which underscores expectations for meaningful recovery/value creation over the coming years. MarketBeat: HC Wainwright Estimates
• Neutral Sentiment: The Q4 2025 earnings call transcript is available for investors who want management detail on results, guidance and program timelines — useful for due diligence but not a single catalyst. Earnings Call Transcript
• Negative Sentiment: HC Wainwright trimmed its FY2028 EPS estimate to $0.58 from $0.68 — a pullback in medium-term profitability expectations that can weigh on sentiment and be a source of profit-taking. MarketBeat: Estimate Revision
• Negative Sentiment: HC Wainwright slightly lowered its FY2026 EPS estimate to $1.05 from $1.06 — a modest downgrade but consistent with the theme of trimmed near-term forecasts. MarketBeat: Estimate Revision

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.